

Curriculum Vitae

Nora Drick PD. Dr. med.
d.o.b. December 21st, 1985, in Berlin, Germany

Current Position Functioning Attending Physician in the Department of Respiratory Medicine,
Head of outpatient clinic for severe Asthma

University Education

2005-2012 Medical School (University of Göttingen)
2012 Medical License Germany (Approbation)
2012 M.D.-Thesis (Dr. med) - The influence of dimethylfumarate and monomethylfumarate on endothelial antigen expression and dynamic lymphocyte-endothelial cell interactions. (Summa cum laude). Supervision by Prof. Dr. M.P. Schön
2019 Board Certification Internal Medicine and Pulmonology
2019/2020 2019-2020 Certificate of medical didactical qualification (MQ I & II)
01/2026 Habilitation Respiratory Medicine, Medical School Hannover

Academic and Scientific career

2012-2019 Medical Residency at MHH Department of Respiratory Medicine (Head of Department: Prof T Welte)
2016-2019 Scholar of the Clinician Scientist Programme of Hannover Medical School, Supervision by Prof. T Welte and Prof. U Martin
Since 2025 Principal Investigator Deutsches Zentrum für Lungenforschung (DZL) Disease Area: Asthma and Allergy

Top-10 selected Publications

Brinkmann L, Fuge J, Welte T, Suhling H*, **Drick N***. Anti-IL-5/anti-IL-5R α treatment improves self-reported work productivity in patients with severe eosinophilic asthma – a prospective cohort trial. ERJ Open Research 2024; 10(6): 00374-2024; * joint last authorship

Beyer S, Haufe S, Dirks M, Scharbau M, Lampe V, Dopfer-Jablonka A, Tegtbur U, Pink I, **Drick N***, Kerling A*. Post-COVID-19 syndrome: Physical capacity, fatigue and quality of life. PLoS One. 2023 Oct 23;18(10): e0292928. * joint last authorship

Drick N, Brinkmann L, Fuge J, Welte T, Suhling H. Influence of anti-IL-5/anti-IL-5R α treatment on work productivity in patients with severe eosinophilic asthma (2023) ERJ Open Res. 2023 May 2;9(3):00665-2022.

Drick N*, Fuge J*, Seeliger B, Speth M, Vogel-Claussen J, Welte T, Suhling H. Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD. ERJ Open Res. 2022 Oct 24;8(4):00207-2022. doi: 10.1183/23120541.00207-2022. * joint first authorship

Drick N*, Milger K*, Seeliger B, Fuge J, Korn S, Buhl R, Schuhmann M, Herth F, Kendziora B, Behr J, Kneidinger N, Bergmann KC, Taube C., Welte T, Suhling H. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma. (2020) J Asthma Allergy 11;13: 605-614. * joint first authorship

Drick N, Dahlmann J, Sahabian A, Haase A, Göhring G, Lachmann N, Ringshausen FC, Welte T, Martin U, Olmer R. Generation of two human induced pluripotent stem cell lines (MHHi017-A, MHHi017-B) from a patient with primary ciliary dyskinesia carrying a homozygous mutation (c.7915C > T [p.Arg2639*]) in the DNAH5 gene (2020). *Stem Cell Res.* 46: 101848.

Drick N, Sahabian A, Pongpamorn P, Merkert S, Göhring G, Welte T, Martin U, Olmer R. Generation of a NKX2.1 - p63 double transgenic knock-in reporter cell line from human induced pluripotent stem cells (MHHi006-A-4) (2020). *Stem Cell Res.* 42: 101659.

Drick N, Seeliger B, Welte T, Fuge J, Suhling H. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response (2018). *BMC Pulm Med* 18; 18(1): 119 Habilitationsunterlagen Publikationsverzeichnis Nora Drick

Drick N, Seeliger B, Fuge J, Tudorache I, Greer M, Welte T, Haverich A, Gottlieb J. Selfreported non-adherence to immunosuppressive medication in adult lung transplant recipients - A single center cross-sectional study. *Clin Transplant* (2018) 29

Drick N*, Seeliger B*, Greer M, Bollmann BA; Ziesing S, Welte T, Gottlieb J. DNA-Based Testing in Lung Transplant Recipients With Suspected Non-Viral Lower Respiratory Tract Infection - A Prospective Observational Study. *Transpl Infect Dis* (2018) 20(1) * joint first authorship